Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes

2001 ◽  
Vol 18 (8) ◽  
pp. 619-625 ◽  
Author(s):  
E. Witthaus ◽  
J. Stewart ◽  
C. Bradley
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Glargine ◽  
Treatment Satisfaction ◽  
Well Being ◽  
Psychological Well Being

scholarly journals Sustained Intensive treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in persons with type 1 diabetes treated with MDI

2020 ◽  
Author(s):  
Marcus Lind ◽  
Arndís F. Ólafsdóttir ◽  
Irl B. Hirsch ◽  
Jan Bolinder ◽  
Sofia Dahlqvist ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Treatment Satisfaction ◽  
Glucose Monitoring ◽  
Well Being ◽  
Diabetes Distress ◽  
Control Treatment ◽  
Long Term Effects ◽  
Self Monitoring

Objective: Continuous Glucose Monitoring (CGM) reduces HbA1c and time spent in hypoglycemia in persons with type 1 diabetes treated with multiple daily insulin injections (MDI) when evaluated over shorter time periods. It is unclear to what extent CGM improves and helps to maintain glucose control, treatment satisfaction, diabetes distress, hypoglycemic concerns and overall well-being over longer periods of time <p><br> Research design and methods: The GOLD trial was a randomized crossover trial performed over 16 months of CGM treatment in persons with type 1 diabetes treated with MDI. Persons completing the trial (n=141) were invited to participate in the current SILVER extension study in which 107 patients continued CGM treatment over 1 year along with the support of a diabetes nurse every 3 months. <br> <br> </p> <p>Results: The primary endpoint, change in HbA1c over 1.0-1.5 years CGM use compared with previous self-monitoring of blood glucose (SMBG) during GOLD, showed a decrease in HbA1c of 0.35% (95% CI 0.19-0.50), p<0.001. Time spent in hypoglycemia <3.0 mmol/l (54 mg/dl) and <4.0 mmol/l (72 mg/dl) decreased from 2.1% to 0.6% (p<0.001) and from 5.4% to 2.9% (p<0.001), respectively. Overall well-being (WHO-5, p=0.009), treatment satisfaction (DTSQ, p<0.001) and hypoglycemic confidence (p<0.001) increased, while hypoglycemic fear (HFS-Worry, p=0.016) decreased and diabetes distress tended to decrease (PAID, p=0.06). From randomization and screening in GOLD, HbA1c was lowered by 0.45% (p<0.001) and 0.68% (p<0.001) after 2.3 and 2.5 years, respectively. <br> <br> Conclusions: The SILVER study supports beneficial long-term effects from CGM on HbA1c, hypoglycemia, treatment satisfaction, well-being and hypoglycemic confidence in persons with T1D managed with MDI. </p>

scholarly journals Psychological Well-Being of Carers of Children with Type 1 Diabetes: A Comparison with Carers of Children without a Chronic Condition

2018 ◽  
Vol 06 (02) ◽  
pp. 096-103 ◽  
Author(s):  
Francesca Thomson ◽  
Philip Bergman ◽  
Margaret Hay
Keyword(s):  
Type 1 Diabetes ◽  
Parenting Stress ◽  
Chronic Condition ◽  
Short Form ◽  
Well Being ◽  
Stress Index ◽  
Online Questionnaire ◽  
Psychological Well Being ◽  
Increased Risk

Abstract Context Caring for a child with a chronic illness requires additional responsibilities and burdens. Aims This research examined psychological well-being of carers of children with type 1 diabetes mellitus (T1DM). A comparison group of carers of children without a chronic condition was included to determine the specific influence T1DM has on carer well-being. Methods This cross-sectional correlational study included a sample of 93 carers of children with T1DM, and 84 comparison carers. Participants were administered the 21-item Depression, Anxiety, and Stress Scale (DASS21), and the Parenting Stress Index Short Form 4th edition via an online questionnaire. Results Multivariate analysis revealed no significant differences between carer groups; additional univariate analyses, however, indicated that carers of children with T1DM scored significantly higher on depression and stress subscales on the DASS21, and recorded elevated anxiety scores. Conclusions Carers of children with T1DM appear to manage parenting stress; however, they may be at increased risk of depression, general stress, and anxiety.

scholarly journals Cognitive Performance, Psychological Well-Being, and Brain Magnetic Resonance Imaging in Older Patients With Type 1 Diabetes

Diabetes ◽  
2006 ◽  
Vol 55 (6) ◽  
pp. 1800-1806 ◽  
Author(s):  
A. M.A. Brands ◽  
R. P.C. Kessels ◽  
R. P.L.M. Hoogma ◽  
J. M.L. Henselmans ◽  
J. W. van der Beek Boter ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Type 1 Diabetes ◽  
Magnetic Resonance ◽  
Cognitive Performance ◽  
Older Patients ◽  
Brain Magnetic Resonance Imaging ◽  
Well Being ◽  
Resonance Imaging ◽  
Psychological Well Being

scholarly journals Sustained Intensive treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in persons with type 1 diabetes treated with MDI

2020 ◽  
Author(s):  
Marcus Lind ◽  
Arndís F. Ólafsdóttir ◽  
Irl B. Hirsch ◽  
Jan Bolinder ◽  
Sofia Dahlqvist ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Treatment Satisfaction ◽  
Glucose Monitoring ◽  
Well Being ◽  
Diabetes Distress ◽  
Control Treatment ◽  
Long Term Effects ◽  
Self Monitoring

Objective: Continuous Glucose Monitoring (CGM) reduces HbA1c and time spent in hypoglycemia in persons with type 1 diabetes treated with multiple daily insulin injections (MDI) when evaluated over shorter time periods. It is unclear to what extent CGM improves and helps to maintain glucose control, treatment satisfaction, diabetes distress, hypoglycemic concerns and overall well-being over longer periods of time <p><br> Research design and methods: The GOLD trial was a randomized crossover trial performed over 16 months of CGM treatment in persons with type 1 diabetes treated with MDI. Persons completing the trial (n=141) were invited to participate in the current SILVER extension study in which 107 patients continued CGM treatment over 1 year along with the support of a diabetes nurse every 3 months. <br> <br> </p> <p>Results: The primary endpoint, change in HbA1c over 1.0-1.5 years CGM use compared with previous self-monitoring of blood glucose (SMBG) during GOLD, showed a decrease in HbA1c of 0.35% (95% CI 0.19-0.50), p<0.001. Time spent in hypoglycemia <3.0 mmol/l (54 mg/dl) and <4.0 mmol/l (72 mg/dl) decreased from 2.1% to 0.6% (p<0.001) and from 5.4% to 2.9% (p<0.001), respectively. Overall well-being (WHO-5, p=0.009), treatment satisfaction (DTSQ, p<0.001) and hypoglycemic confidence (p<0.001) increased, while hypoglycemic fear (HFS-Worry, p=0.016) decreased and diabetes distress tended to decrease (PAID, p=0.06). From randomization and screening in GOLD, HbA1c was lowered by 0.45% (p<0.001) and 0.68% (p<0.001) after 2.3 and 2.5 years, respectively. <br> <br> Conclusions: The SILVER study supports beneficial long-term effects from CGM on HbA1c, hypoglycemia, treatment satisfaction, well-being and hypoglycemic confidence in persons with T1D managed with MDI. </p>

Sign in / Sign up

Export Citation Format

Share Document